Figure 1

OSBPL3 expression, DNA copy number, and promoter methylation in GC. (a) DNA copy number variations according to chromosome arm in 441 GC tissues from TCGA. (b) OSBPL3 mRNA expression in 109 tumor tissues and 109 paired normal tissues from our GC patient cohort (left panel) and in 415 tumor tissues and 35 normal tissues from GC patients in TCGA (right panel). T: tumor tissue; N: normal tissue. Mann–Whitney U test. (c) Immunohistochemical analysis of OSBPL3 in representative samples from our GC patient cohort. Original magnification, × 50 (upper) and ×400 (lower). T: tumor tissue; N: normal tissue. (d) Correlation between OSBPL3 mRNA expression and DNA copy number (log 2(N/2)) in 413 GC patients from TCGA and 38 GC cell lines from the CCLE. (e) OSBPL3 mRNA expression in 185 GC patients exhibiting OSBPL3 promoter hypomethylation and 185 GC patients exhibiting OSBPL3 promoter hypermethylation from TCGA (left panel). OSBPL3 mRNA expression in 17 GC cell lines exhibiting OSBPL3 promoter hypomethylation and 17 GC cell lines exhibiting OSBPL3 promoter hypermethylation from the CCLE (right panel). Mann–Whitney U test. (f) An integrated view of the mRNA expression, DNA copy number, promoter methylation, and mutation profiles of OSBPL3 in 370 GC cases from TCGA. The samples are sorted according to the OSBPL3 mRNA expression level. (g) The mRNA expression levels of OSBP family members in 415 tumor tissues compared with 35 normal tissues of GC patients from TCGA. Mann–Whitney U test and FDR-controlling procedures were performed.